Evaluation of Some Immunological Markers in Patients with Acute Pyelonephritis Caused by Proteus mirabilis
DOI:
https://doi.org/10.46966/msjar.v7i2.431Keywords:
Immune markers, pyelonephritis, P. mirabilisAbstract
Background: Acute pyelonephritis caused by Proteus mirabilis is a severe urinary tract infection considered by deep tissue inflammation; microRNAs and chemokine’s play vital roles in regulating the host immune response. This study goals to evaluate the disease station and determine the diagnostic efficacy of the immune axis linking miR-370 and CCL2 in patient serum. Methodology: This study employed a case-control design involving a overall sample of 120 individuals, comprising 60 patients with P.mirabilis persuaded pyelonephritis and 60 healthy controls. Demographic data were recorded, and miR-370 gene expression levels were assessed using quantitative real-time PCR , while serum CCL2 concentrations were measured via enzyme-linked immunosorbent assay . Statistical analyses included Pearson correlation and receiver operating characteristic (ROC) curve analysis. Results: Clinical valuation showed that fever (75%) and flank pain (50%) were the greatest common symptoms. Immunological analysis revealed lesser miR-370 expression levels in patients (0.55 ± 0.01) compared to healthy controls (1.89 ± 0.02) at P < 0.001, while serum CCL2 concentrations were higher in patients (11.45 ± 0.011) vs. control (1.26 ± 0.017) pg/mL at P < 0.001. A strong negative correlation was experiential between the two markers (r = -0.645, P < 0.001). Combining the two indicators into a diagnostic panel reached high discriminative accurateness, with an area under the curve of 0.954, sensitivity of 92.0%, and 90.5%. of a specificity. Conclusion: The present study confirms that pyelonephritis causes a profound disturbance characterized by the loss of miR-370-mediated immune-regulatory suppression, leading to a marked increase in serum CCL2 levels. This dual-biomarker panel serves as an accurate, non-invasive tool for the early diagnosis of acute kidney injury.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Layla Saleh Abdul-Hassan

This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


















